Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 2Sarcoma 1Lymphoid 1Dermatologic 1

Conditions

Uterine Cervical Dysplasia 2Squamous Intraepithelial Lesions 2Skin Neoplasms 1Sarcoma, Kaposi 1Lymphoproliferative Disorders 1HIV Infections 1Acquired Immunodeficiency Syndrome 1

Interventions

Paclitaxel 489Carboplatin 435Gemcitabine 394Docetaxel 385Cisplatin 359pembrolizumab 343Bevacizumab 335Nivolumab 261Pemetrexed 242Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 91

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × INDUSTRY × 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone × Clear all
NCT00285207 2010-10-11

Safety and Efficacy of A-007 Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix

Tigris Pharmaceuticals

Phase 2 Completed
147 enrolled 6 charts
Gynecologic

Squamous Intraepithelial Lesions, Uterine Cervical Dysplasia

NCT00596258 2009-05-22

TG-003

Tigris Pharmaceuticals

Phase 2 Completed
11 enrolled
Gynecologic

Squamous Intraepithelial Lesions, Uterine Cervical Dysplasia

NCT00002153 2005-06-24

Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders

NIH AIDS Clinical Trials Information Service

Phase 1 Completed
25 enrolled
DermatologicLymphoidSarcoma

Acquired Immunodeficiency Syndrome, Lymphoproliferative Disorders, Sarcoma, Kaposi, Skin Neoplasms, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡